H.C. Wainwright analyst Yi Chen raised the firm’s price target on Tempus AI (TEM) to $95 from $89 and keeps a Buy rating on the shares. Tempus AI continues to expand strategic partnerships, including collaborations with Merck (MRK), Median Technologies, and NYU Langone Health, to advance precision medicine, AI-driven diagnostics, and cancer research through its data platforms and molecular profiling capabilities, the analyst tells investors in a research note.
Claim 55% Off TipRanks
Forget margin or options. Here's how the pros trade TEMPublished first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEM:
- Tempus AI management to meet with Needham
- Tempus AI, Merck announce AI-driven precision medicine collaboration
- Tempus AI price target lowered to $70 from $85 at Morgan Stanley
- XAIX, AGIX: Two Best Artificial Intelligence (AI) ETFs to Buy Now
- Cathie Wood’s ARK Investment buys 213K shares of Tempus AI today